Entrada Therapeutics Earnings Estimate

TRDA Stock  USD 19.89  0.06  0.30%   
The next projected EPS of Entrada Therapeutics is estimated to be 0.256875 with future projections ranging from a low of 0.2275 to a high of 0.2975. Entrada Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at 1.44. Please be aware that the consensus of earnings estimates for Entrada Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Entrada Therapeutics is projected to generate 0.256875 in earnings per share on the 31st of December 2024. Entrada Therapeutics earnings estimates module stress-tests analyst consensus about projected Entrada Therapeutics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Entrada Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Entrada Therapeutics' earnings estimates, investors can diagnose different trends across Entrada Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about 30.6 M, whereas Pretax Profit Margin is forecasted to decline to 0.07.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.

Entrada Therapeutics Earnings Estimation Breakdown

The calculation of Entrada Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Entrada Therapeutics is estimated to be 0.256875 with the future projection ranging from a low of 0.2275 to a high of 0.2975. Please be aware that this consensus of annual earnings estimates for Entrada Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.35
0.23
Lowest
Expected EPS
0.256875
0.30
Highest

Entrada Therapeutics Earnings Projection Consensus

Suppose the current estimates of Entrada Therapeutics' value are higher than the current market price of the Entrada Therapeutics stock. In this case, investors may conclude that Entrada Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Entrada Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2024Current EPS (TTM)
528.69%
-0.35
0.256875
1.44

Entrada Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of Entrada Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Entrada Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Entrada Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Entrada Therapeutics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Entrada Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Entrada Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

Entrada Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Entrada Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-05
2024-09-30-0.625-0.350.27544 
2024-08-06
2024-06-300.141.54991.40991007 
2024-05-07
2024-03-31-0.590.681.27215 
2024-03-13
2023-12-31-0.17-0.29-0.1270 
2023-11-07
2023-09-30-0.741.021.76237 
2023-08-08
2023-06-30-0.69-0.78-0.0913 
2023-05-10
2023-03-310.97-0.21-1.18121 
2023-03-06
2022-12-31-0.83-0.790.04
2022-11-07
2022-09-30-0.76-0.8-0.04
2022-08-11
2022-06-30-0.72-0.74-0.02
2022-05-12
2022-03-31-0.65-0.69-0.04
2022-03-15
2021-12-31-1.28-0.890.3930 
2021-12-09
2021-09-30-0.87-9.78-8.911024 
2021-09-01
2021-06-300-0.45-0.45
2021-06-30
2021-03-310-7.0819-7.0819
2021-03-31
2020-12-310-7.0819-7.0819
2020-06-30
2020-03-310-5.1812-5.1812
2020-03-31
2019-12-310-5.1812-5.1812

About Entrada Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Entrada Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Entrada Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Entrada Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-195 M-185.2 M
Retained Earnings Total Equity-84.3 M-88.5 M
Earnings Yield(0.01)(0.01)
Price Earnings Ratio(74.60)(78.33)
Price Earnings To Growth Ratio 0.80  0.84 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.44
Revenue Per Share
6.074
Quarterly Revenue Growth
(0.55)
Return On Assets
0.0695
Return On Equity
0.1642
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.